Endogenex Secures $88 Million in Series C Funding to Advance Breakthrough Diabetes Treatment
Endogenex, a pioneering clinical-stage medical device company dedicated to transforming diabetes care, has successfully closed an oversubscribed Series C financing round, raising a remarkable $88 million. This substantial funding boost will propel the company towards completing its pivotal ReCET Clinical Study, a critical step in bringing their innovative ReCET™ System to market for patients suffering…
